Abstract
In neurological insults, such as cerebral ischemia and traumatic brain injury, complex molecular mechanisms involving inflammation and apoptosis are known to cause severe neuronal cell loss, emphasizing the necessity of developing therapeutic strategies targeting simultaneously these two processes. Over the last decade, numerous in vitro and in vivo studies have demonstrated the unique therapeutical potential of pituitary adenylate cyclase-activating polypeptide (PACAP) for the treatment of neuronal disorders involving apoptotic cell death and neuroinflammation. The neuroprotective activity of PACAP is based on its capacity to reduce the production of deleterious cytokines from activated microglia, to stimulate the release of neuroprotective agents from astrocytes and to inhibit proapoptotic intracellular pathways. However, the use of PACAP as a clinically applicable drug is hindered by its peptidic nature. As most natural peptides, native PACAP shows poor metabolic stability, low bioavailability, inadequate distribution and rapid blood clearance. Moreover, injection of PACAP to human can induce peripheral adverse side effects. Therefore, targeted chemical modifications and/or conjugation of PACAP to different macromolecules are required to improve the pharmacokinetic and pharmacological properties of PACAP. This review presents the chemical, biochemical and pharmacological strategies that are currently under development to convert PACAP from a hypophysiotropic neurohormone into a clinically relevant neuroprotective drug.
Keywords: PACAP, VIP, Neuroprotection, Stroke, Traumatic brain injury, G protein-coupled receptor, Bioactive conformation, Peptide drug design, hypophysiotropic, methionine, insulinotropic, helodermin, N-glycosylation, inositol, dromotropic, phosphorylation, apurinic, threonine, encephalomyelitis, inducesthe
Current Pharmaceutical Design
Title: Strategies to Convert PACAP from a Hypophysiotropic Neurohormone Into a Neuroprotective Drug
Volume: 17 Issue: 10
Author(s): S. Bourgault, D. Chatenet, O. Wurtz, N. D. Doan, J. Leprince, H. Vaudry, A. Fournier and D. Vaudry
Affiliation:
Keywords: PACAP, VIP, Neuroprotection, Stroke, Traumatic brain injury, G protein-coupled receptor, Bioactive conformation, Peptide drug design, hypophysiotropic, methionine, insulinotropic, helodermin, N-glycosylation, inositol, dromotropic, phosphorylation, apurinic, threonine, encephalomyelitis, inducesthe
Abstract: In neurological insults, such as cerebral ischemia and traumatic brain injury, complex molecular mechanisms involving inflammation and apoptosis are known to cause severe neuronal cell loss, emphasizing the necessity of developing therapeutic strategies targeting simultaneously these two processes. Over the last decade, numerous in vitro and in vivo studies have demonstrated the unique therapeutical potential of pituitary adenylate cyclase-activating polypeptide (PACAP) for the treatment of neuronal disorders involving apoptotic cell death and neuroinflammation. The neuroprotective activity of PACAP is based on its capacity to reduce the production of deleterious cytokines from activated microglia, to stimulate the release of neuroprotective agents from astrocytes and to inhibit proapoptotic intracellular pathways. However, the use of PACAP as a clinically applicable drug is hindered by its peptidic nature. As most natural peptides, native PACAP shows poor metabolic stability, low bioavailability, inadequate distribution and rapid blood clearance. Moreover, injection of PACAP to human can induce peripheral adverse side effects. Therefore, targeted chemical modifications and/or conjugation of PACAP to different macromolecules are required to improve the pharmacokinetic and pharmacological properties of PACAP. This review presents the chemical, biochemical and pharmacological strategies that are currently under development to convert PACAP from a hypophysiotropic neurohormone into a clinically relevant neuroprotective drug.
Export Options
About this article
Cite this article as:
Bourgault S., Chatenet D., Wurtz O., D. Doan N., Leprince J., Vaudry H., Fournier A. and Vaudry D., Strategies to Convert PACAP from a Hypophysiotropic Neurohormone Into a Neuroprotective Drug, Current Pharmaceutical Design 2011; 17 (10) . https://dx.doi.org/10.2174/138161211795589337
DOI https://dx.doi.org/10.2174/138161211795589337 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Advances in Stem Cells Transplantation for the Therapy of Parkinson’s Disease
Current Stem Cell Research & Therapy Natural compound-derived epigenetic regulators targeting epigenetic readers, writers and erasers
Current Topics in Medicinal Chemistry Antioxidant Effects of Coumarins Include Direct Radical Scavenging, Metal Chelation and Inhibition of ROS-Producing Enzymes
Current Topics in Medicinal Chemistry Polymorphism in Endothelin-1 Gene: An Overview
Current Clinical Pharmacology Taurine and the Relevance of Supplementation in Humans, in Health and Disease
Current Nutrition & Food Science Editorial: Cocaine and Cerebral Small Vessel: Is it a Negative Factor for Intravenous Thrombolysis?
Current Vascular Pharmacology PDE7-Selective and Dual Inhibitors: Advances in Chemical and Biological Research
Current Medicinal Chemistry Dual Carbonic Anhydrase - Cyclooxygenase-2 Inhibitors
Current Topics in Medicinal Chemistry The Neurotachykinin NK1 Receptor – A Novel Target for Diagnostics and Therapy
Current Molecular Imaging (Discontinued) The Role of Platelets in Athero-Thrombotic Events
Current Pharmaceutical Design Cathinone Neurotoxicity (“The “3Ms”)
Current Neuropharmacology Therapeutic Potential and Mechanisms of Action of Mesenchymal Stromal Cells for Acute Respiratory Distress Syndrome
Current Stem Cell Research & Therapy Endogenous and Exogenous CNS Derived Stem / Progenitor Cell Approaches for Neurotrauma
Current Drug Targets Delivery Systems of Opioid Analgesics for Pain Relief: A Review
Current Pharmaceutical Design Association Between Preoperative Midline Shift Growing Rate and Outcomes of Decompressive Craniectomy in Patients with Malignant Middle Cerebral Artery Infarction
Current Neurovascular Research Stroke and Neuroinflamation: Role of Sexual Hormones
Current Pharmaceutical Design Purinergic Signaling and Hippocampal Long-Term Potentiation
Current Neuropharmacology Current Signal Transduction Therapy for Brain Tumors Review Article
Current Signal Transduction Therapy Recent progress in the development of anthrax vaccines
Recent Patents on Biotechnology Targeting Apelinergic System in Cardiometabolic Disease
Current Drug Targets